Market Cap 127.73M
Revenue (ttm) 10.68M
Net Income (ttm) -27.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -260.49%
Debt to Equity Ratio 0.09
Volume 1,905,100
Avg Vol 45,556
Day's Range N/A - N/A
Shares Out 30.05M
Stochastic %K 0%
Beta 0.52
Analysts Strong Sell
Price Target $12.31

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices
Sector: Healthcare
Phone: 647 476 1350
Fax: 647 847 3739
Address:
2400 Skymark Avenue, Unit 6, Mississauga, Canada
Baba200TradeBot
Baba200TradeBot Aug. 18 at 2:01 PM
lowfloatreport.com/ - $PROF Attempt 1 failed with status code 429. Retrying... Attempt 2 failed with status code 429. Retrying... Attempt 3 failed with status code 429. Retrying... Error: Unable to generate response after retries.
0 · Reply
Baba200TradeBot
Baba200TradeBot Aug. 18 at 2:00 PM
LowFloatReport.com - 🔥 - Top 5 Low Float High Relative Volume (Post Market Open) as of 08/18/25 - 10:00 AM $PPCB - Volume: 33.6M - Prev Volume: 3K - Float: 11.6 - Rel Vol: 20115.6x - Chng%: +177.5% $VTAK - Volume: 35.7M - Prev Volume: 1.2M - Float: 1.17 - Rel Vol: 378.7x - Chng%: +52.1% $NVFY - Volume: 4.8M - Prev Volume: 42K - Float: 9.64 - Rel Vol: 365.1x - Chng%: -15.2% $PROF - Volume: 1.5M - Prev Volume: 41K - Float: 26.58 - Rel Vol: 251.8x - Chng%: +2.9% $ENLV - Volume: 6.3M - Prev Volume: 950K - Float: 22.66 - Rel Vol: 216.8x - Chng%: -26.4%
0 · Reply
johntarlick
johntarlick Aug. 17 at 1:10 PM
$PROF I'm inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs 'pipeline' on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can't imagine those numbers aren't to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.
1 · Reply
mlanthoo
mlanthoo Aug. 16 at 3:28 PM
$PROF it seems this management team overpromises and underdelivers on an ongoing basis . time for new direction as current management isn't getting the job done . always an excuse .
0 · Reply
Basic_Trader01
Basic_Trader01 Aug. 15 at 5:07 PM
$PROF the end is near, need for leadership change.
0 · Reply
johntarlick
johntarlick Aug. 8 at 12:29 PM
wow PCRT just imploded. i hadn't been following it closely and I had thought to move to pursue cancer clearance was generally correct. But apparently the stock price was run up out of all proportion to that opportunity, and that combined with c-suite churnover resulted in a meltdown. normally i wouldn't jump to conclusions, but I do think this opens the door for $PROF to pick up some new investors/attention.
1 · Reply
BioTuesdays
BioTuesdays Jul. 29 at 9:40 PM
Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA $PROF https://biotuesdays.com/2025/07/29/cook-medicals-launch-of-new-imri-division-may-help-pave-the-way-for-wider-and-faster-adoption-of-innovative-procedures-like-profounds-tulsa/
4 · Reply
BioTuesdays
BioTuesdays Jul. 16 at 7:58 PM
Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical, reiterating his ‘buy’ rating and $11 target price on the company’s stock $PROF https://biotuesdays.com/2025/07/16/lake-street-sees-cmss-proposed-2026-tulsa-reimbursement-as-favorable/
1 · Reply
dndodd
dndodd Jul. 14 at 11:44 AM
$PROF as a follow up to a friend I introduced to Tulsa. He chose Tulsa over DaVinci (which was scheduled). He is very happy with end result no surgery and his prostate is shrunk or gone. The only complications was he had to have a catheter a little longer than expected as they totally did away with the prostrate. He traveled 500 miles to go the Tulsa route. We have a great medical community in Birmingham, Al but someone needs to be the first to buy a Tulsa as I am sure it would be a success.
0 · Reply
johntarlick
johntarlick Jul. 13 at 12:06 PM
$PROF a strange business. Over on glassdoor, it's being said a round of layoffs in the sales team took effect on July 1. Not sure what to make of this. By my tally, the 2020-2024 sales team had never numbered more than about 20. But, since the new CCO came on board last fall, it had been publicly stated that he'd be getting a sales team of no less than 40. That hadn't seemed realistic to me, but i did at least appreciate the intent of going all in on driving sales and building revenue. Now it seems like that's being walked back a little.
0 · Reply
Latest News on PROF
Profound Medical: Smokes Is Everywhere, Initiate At Sell

Aug 18, 2025, 7:01 PM EDT - 2 hours ago

Profound Medical: Smokes Is Everywhere, Initiate At Sell

PRN


Profound Medical AUA 2025 Investor Event Agenda

Apr 15, 2025, 7:45 AM EDT - 4 months ago

Profound Medical AUA 2025 Investor Event Agenda


Baba200TradeBot
Baba200TradeBot Aug. 18 at 2:01 PM
lowfloatreport.com/ - $PROF Attempt 1 failed with status code 429. Retrying... Attempt 2 failed with status code 429. Retrying... Attempt 3 failed with status code 429. Retrying... Error: Unable to generate response after retries.
0 · Reply
Baba200TradeBot
Baba200TradeBot Aug. 18 at 2:00 PM
LowFloatReport.com - 🔥 - Top 5 Low Float High Relative Volume (Post Market Open) as of 08/18/25 - 10:00 AM $PPCB - Volume: 33.6M - Prev Volume: 3K - Float: 11.6 - Rel Vol: 20115.6x - Chng%: +177.5% $VTAK - Volume: 35.7M - Prev Volume: 1.2M - Float: 1.17 - Rel Vol: 378.7x - Chng%: +52.1% $NVFY - Volume: 4.8M - Prev Volume: 42K - Float: 9.64 - Rel Vol: 365.1x - Chng%: -15.2% $PROF - Volume: 1.5M - Prev Volume: 41K - Float: 26.58 - Rel Vol: 251.8x - Chng%: +2.9% $ENLV - Volume: 6.3M - Prev Volume: 950K - Float: 22.66 - Rel Vol: 216.8x - Chng%: -26.4%
0 · Reply
johntarlick
johntarlick Aug. 17 at 1:10 PM
$PROF I'm inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs 'pipeline' on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can't imagine those numbers aren't to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.
1 · Reply
mlanthoo
mlanthoo Aug. 16 at 3:28 PM
$PROF it seems this management team overpromises and underdelivers on an ongoing basis . time for new direction as current management isn't getting the job done . always an excuse .
0 · Reply
Basic_Trader01
Basic_Trader01 Aug. 15 at 5:07 PM
$PROF the end is near, need for leadership change.
0 · Reply
johntarlick
johntarlick Aug. 8 at 12:29 PM
wow PCRT just imploded. i hadn't been following it closely and I had thought to move to pursue cancer clearance was generally correct. But apparently the stock price was run up out of all proportion to that opportunity, and that combined with c-suite churnover resulted in a meltdown. normally i wouldn't jump to conclusions, but I do think this opens the door for $PROF to pick up some new investors/attention.
1 · Reply
BioTuesdays
BioTuesdays Jul. 29 at 9:40 PM
Cook Medical’s launch of new iMRI division may help pave the way for wider and faster adoption of innovative procedures, like Profound’s TULSA $PROF https://biotuesdays.com/2025/07/29/cook-medicals-launch-of-new-imri-division-may-help-pave-the-way-for-wider-and-faster-adoption-of-innovative-procedures-like-profounds-tulsa/
4 · Reply
BioTuesdays
BioTuesdays Jul. 16 at 7:58 PM
Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical, reiterating his ‘buy’ rating and $11 target price on the company’s stock $PROF https://biotuesdays.com/2025/07/16/lake-street-sees-cmss-proposed-2026-tulsa-reimbursement-as-favorable/
1 · Reply
dndodd
dndodd Jul. 14 at 11:44 AM
$PROF as a follow up to a friend I introduced to Tulsa. He chose Tulsa over DaVinci (which was scheduled). He is very happy with end result no surgery and his prostate is shrunk or gone. The only complications was he had to have a catheter a little longer than expected as they totally did away with the prostrate. He traveled 500 miles to go the Tulsa route. We have a great medical community in Birmingham, Al but someone needs to be the first to buy a Tulsa as I am sure it would be a success.
0 · Reply
johntarlick
johntarlick Jul. 13 at 12:06 PM
$PROF a strange business. Over on glassdoor, it's being said a round of layoffs in the sales team took effect on July 1. Not sure what to make of this. By my tally, the 2020-2024 sales team had never numbered more than about 20. But, since the new CCO came on board last fall, it had been publicly stated that he'd be getting a sales team of no less than 40. That hadn't seemed realistic to me, but i did at least appreciate the intent of going all in on driving sales and building revenue. Now it seems like that's being walked back a little.
0 · Reply
johntarlick
johntarlick Jul. 4 at 2:15 AM
another Canadian medtech with some parallels to $PROF (Synaptive) has just emerged from bankruptcy, with some new investment and an unknown future. Much like $PROF, they pioneered a new surgical tool with image-guidance. Like TulsaPro, the Synaptive exoscope was technically best in class. Like $PROF, Synaptive struggled to place many systems. Like $PROF, Synaptive was small and somewhat under-funded compared to the competition. To be clear, Synaptive made a certain mistake that $PROF has not made. Perhaps two. But still, Synaptive was loaded to the gills with talent. It had seemed just a few years ago that their future was bright.
0 · Reply
johntarlick
johntarlick Jun. 25 at 11:33 AM
not super new, but i only just caught it. the original founder of $PROF recently co-founded a boutique concierge prostate clinic to offer tulsaPRO in Texas. Interestingly, that clinic also offers HIFU. If the founder of $PROF thinks HIFU is still a viable choice, it nicely informs the comparative long term prospects for these two related technologies.
2 · Reply
dndodd
dndodd Jun. 22 at 1:27 PM
$PROF this company seems to be totally flying under the radar of many investors. At some point it will be seen for the game changer it is.
0 · Reply
QES
QES Jun. 12 at 12:42 AM
$PROF How PROF compares to $PRCT PROF is the clear winner
3 · Reply
BioTuesdays
BioTuesdays Jun. 10 at 5:24 PM
First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction $PROF https://biotuesdays.com/2025/06/10/first-bph-patient-treated-using-profounds-tulsa-pro-with-tulsa-ai-volume-reduction/
1 · Reply
QES
QES Jun. 10 at 5:04 PM
$PROF Naveen Kella, M.D., Founder of The Urology Place "He has performed nearly all of his robotic prostatectomy cases in the same hospital with the same team. " Is he switching to TULSA Pro? https://www.youtube.com/watch?v=H0iedrP-aLI&t=118s
0 · Reply
QES
QES Jun. 10 at 2:26 PM
$PROF Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO® with TULSA-AI® Volume Reduction the first commercial benign prostatic hyperplasia (“BPH”) treatment utilizing the TULSA-PRO® system’s new TULSA-AI® Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio. The TULSA procedure, performed using the TULSA-PRO® system, has the potential to become a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. https://www.globenewswire.com/news-release/2025/06/10/3096565/33471/en/Profound-Medical-Announces-First-Commercial-BPH-Patient-Treatment-Using-TULSA-PRO-with-TULSA-AI-Volume-Reduction.html
0 · Reply
johntarlick
johntarlick Jun. 8 at 12:31 PM
Interesting, according to barchart some insiders bought into that recent dip $PROF, but not the one I'm really watching for.
0 · Reply
johntarlick
johntarlick Jun. 5 at 11:32 AM
$PROF Interesting podcast with CEO posted on the State of Medtech channel, deep dive on a lot of the topics that don't get much detail in the quarterly calls or press releases. But there's also more than a few canards to be aware of. For example, I was a Cedara shareholder back in the day, and what happened there was very different.
1 · Reply
BioTuesdays
BioTuesdays Jun. 4 at 2:48 PM
Profound Medical today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the NFL Legends Community, and national podcaster $PROF https://biotuesdays.com/2025/06/04/leonard-wheeler-former-nfl-player-named-global-ambassador-for-profounds-tulsa-pro/
0 · Reply
QES
QES Jun. 4 at 2:31 PM
$PROF Notice that the hiring of Laurie Vertuccio as the new Vice President of Global Marketing coincides with Profound's newly announced consulting agreement with Leonard Wheeler. “To that end, we are excited to partner with Leonard and look forward to working with him to soon launch an immersive TULSA-PRO® awareness campaign on multiple fronts, including digital media, social media, podcasting, and more.” IMO, the biggest issue for PROF is that essentially nobody knows about TULSA Pro. Looks like that should change rapidly.
0 · Reply